Clinical Trial Update: MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MTI-301 to evaluate safety and initial activity in patients with metastatic, unresectable, or refractory solid tumors; recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor
• Unresectable Solid Tumor

Drugs mentioned

• MTI-301 (MTI-301)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING